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Background and objective. In Poland, the sale of antihypertensive drugs has significantly increased since 
2000. According to that fact, the aim of our study was to determine if the increased use of antihypertensive drugs 
correlates with the decreasing mortality due to cardiovascular diseases (CVD) including hypertension (HT). 
Methods. The analysis is based on data on annual national sales (million units) of four types of antihypertensive 
drugs in 2000–2010. For the same period standardized mortality rates were calculated based on the data available 
from the Central Statistical Office in Poland. Data analysis involved correlation analysis between annual mortality 
rates due CVD and HT and country-wide annual sales of antihypertensive drugs (2000–2010). 
Results. In the period 2000–2010, standardized mortality rates of CVD in the whole population followed a 
decreasing trend. Analysis of correlation of CVD with specific drug provided the following findings: diuretics 
(r=-0.97; p<0.0001) beta-blockers (r=-1.0; p<0.0001) renin-angiotensin system (RAS) inhibitors (r=-0.72 p=0.01) 
calcium-channel blockers (r=-0.82; p=0.001) Standardized mortality rates for the HT showed fluctuating trend. 
Correlations of that mortality with global sale of these drugs were no longer negative: r=0.54; p=0.08, r=0.56; 
p=0.08 r=0.55; p=0.07; r=0.63; p=0.03, respectively. 
Conclusions. In Poland, in 2000–2010, an improved access to pharmacological control of HT was associated 
with an apparent reduction in mortality from CVD but not from HT. The latter findings might reflect imprecise 
definition of HT as a cause of death or the fact that HT leads to other cardiologic events usually reported as a 
cause of death. 
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Introduction
Standardized mortality rates caused by car-
diovascular diseases (CVD) have been de crea-
sing in developed countries since 1980 [1]. In 
Poland, in the last 20 years, CVD mortality 
decreased twice and the dynamics was strong 
between 1990 and 2000 [2]. Many hypotheses 
have addressed the issue, including changes of 
lifestyle and diet, improved access to modern 
medical technologies [3]. Another potential 
factor could be related to better pharmacological 
control of hypertension (HT) [4]. Such an expla-
nation can be explored in ecological manner 
through analysis of correlation between the 
nation-wide sale of hypertensive drugs and 
CVD/HT mortality, over a period of time. 
The major classes of antihypertensive drugs 
include beta-blockers (BB), renin-angiotensin 
system inhibitors (RES), diuretics (D) and cal-
cium channel blockers (CCB). Clinical studies 
confirm that those drugs used in the treatment 
of HT are effective in preventing heart attack 
and stroke [5]. Less is known about population-
based impact of the increased supply of the 
above drugs on ultimate outcome of HT, such 
as CVD mortality. In Poland, increased sales of 
and access to modern antihypertensive drugs 
has occurred over the two last decades and 
annual whole-country sales are available for a 
recent period (2000–2010), thus making such 
analysis possible.
The principal aim of our study was to deter-
mine if the increased use of antihypertensive 
drugs correlates with the decreasing mortality 
due to cardiovascular diseases (CVD) including 
hypertension (HT), in general population of 
Poland. The secondary aim of the study was to 
explore the hypothesized correlation in three 
age groups: 0–44 years, 45–64 years, above 64 
years. 
Materials and Methods
The analysis is based on data on annual 
sales (million units) of four types of antihy per-
tensive drugs in 2000–2010: beta-blockers (BB), 
renin-angiotensin system inhibitors (RES), 
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diuretics (D) and calcium channel blockers 
(CCB). Annual standardized mortality rates due 
to CVD and HT were calculated from raw data 
provided by the reports of the Central Statistical 
Office in Poland, using direct method (reference 
population: WHO European Standard Population 
[6]. Correlation analysis of CVD and HR with 
drug sales (Spearman method) was performed 
for the entire population and for three age 
groups (0 to 44, 45 to 64 and over 64 years of 
age). Statistical significance was assumed at 
p=0.05. All calculations were performed in SAS 
software (version 9.20, SAS Institute, Cary, 
N.C.).
Results 
Standardized mortality rates due to CVD 
(n/100 000) in Polish population between 2000-
2010 were: 439, 428, 412, 412, 391, 377, 365, 358, 
350, 350, 331, respectively. In the same period 
the annual sales of all antihypertensive drugs 
(mln units globally) were: 100, 97, 96, 100, 105, 
117, 123, 134, 143, 154, 158. Figure 1 shows 
annual antihypertensive drugs supply in each 
defined category and annual mortality rates 
due to CVD, over the same period.
 Correlation analysis of CVD mortality with 
the defined classes of drugs showed negative 
and statistically significant coefficients: BB 
(r=-1.0 p<0.001), RES (r=-0.72 p=0.01), D (r=-0.97; 
p<0.001), CCB (r=-0.82 p=0.001). Additional 
analyses involving stratification for age showed 
larger coefficients of correlation in older seg-
ments of the population (Table 1).
Standardized mortality rates due to HT 
(n/100 000) in Polish population between 2000– 
2010 were: 11,73; 10,82; 10,44; 11,30; 11,36; 
12,53; 13,02; 12,60; 11,53; 12,38; 12,0; 10,24, 
respectively. Figure 1 shows annual antihy per-
tensive drugs supply in each defined category 
and annual mortality rates due to HT, over the 
same period.
Trends of antihypertensive drugs supply 
with standardized mortality rate caused with 
HT are shown in Figure 2.
Fig. 1 Annual sales of antihypertensive drugs and CVD standardized mortality rate in 2000-2010 in polish population.
Legends: CVD – cardiovascular diseases, BB – beta-blockers, RES – renin angiotensin system inhibitors, D – diuretics, 
CCB – calcium channel blockers. 
Table 1. Correlation of the supply of selected antihypertensive drugs (BB, RES, D, CCB)  
with CVD standardized mortality rate in polish population between 2000–2010
 
Type of antihypertensive drug
Specified group age BB RES D CCB
0–44 years r=-0.82
p<0.05
r=-0.46
NS*
r=-0.756
p<0.05
r=-0.52
NS*
45–64 years r=-0.99
p<0.05
r=-0.71
p<0.05
r=-0.96
p<0.05
r=-0.82
p<0.05
>64 years r=-0.98
p<0.05
r=-0.72
p<0.05
r=-0.96
p<0.05
r=-0.82
p<0.05
Legends: NS – not significant, BB – beta-blockers, RES – renin angiotensin system inhibitors, D – diuretics, CCB – calcium 
channel blockers.
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Correlation analysis of HT mortality with the 
defined classes of drugs showed negative and 
statistically significant coefficients: Beta-Blo-
ckers (r=0.56 p=0.07), RES (r=0.55 p=0.07), 
Diuretics (r=0.54; p=0.08), CCB (r= 0.63 p=0.03). 
Additional analyses involving stratification for 
age showed larger coefficients of correlation in 
older segments of the population (Table 2).
Discussion 
High mortality due to cardiovascular dise-
ases, seen for decades in the XX century in 
Poland, declined rapidly in 1991–1994. Since 
then the pace of decline is slower, but apparent. 
For example, CVD standardized mortality rates 
significantly decreased from 431 in 2000 to 339 
in 2010. The observed phenomenon is attributed 
to a number of factors, including change of 
lifestyle with particular focus on healthy diet. 
Some estimates suggest that the reduction of 
dietary cholesterol intake in the analyzed period 
has explained a 39% reduction in general 
mortality due to coronary heart disease (CHD), 
Fig. 2 Annual sales of antihypertensive drugs and HT standardized mortality rate in 2000-2010 in polish population.
Legends: HT – hypertension, BB – beta-blockers, RES – renin angiotensin system inhibitors, D – diuretics, CCB – calcium 
channel blockers.
Table 2. Correlation of the supply of selected antihypertensive drugs (BB, RES, D, CCB) with HT 
standardized mortality rate in polish population between 2000–2010 
Type of antihypertensive drug
Specified group age BB RES D CCB
0–44 years r=-0.58
NS*
r=-0.29
NS*
r=-0.52
NS*
r=-0.31
NS*
45–64 years r=0.79
p<0.05
r=0.70
p<0.05
r=0.78
p<0.05
r=0.75
p<0.05
>64 years r=0.92
p<0.05
r=0.76
p<0.05
r=0.87
p<0.05
r=0.83
p<0.05
Legends: NS – not significant, BB – beta-blockers, RES – renin angiotensin system inhibitors, D – diuretics, CCB – calcium 
channel blockers.
in Poland [7]. Other factors include reduced 
smoking and increased physical activity with 
the estimated contribution to decreased CHD 
mortality at the levels of 11% and 10%, respec-
tively [8]. Other studies suggest an important 
role of tobacco smoking cessation (as most 
important cause), followed by blood pressure 
control (10%) and cholesterol (10%) [9]. The role 
of smoking habit together with high density 
lipoprotein cholesterol concentrations, trigly-
ceride concentrations, diabetes, body mass 
index, height, alcohol intake, physical activity, 
and level of education have been also confirmed 
by ecological findings in the Polish population 
[10]. 
Interest in the impact of environmental 
factors on CVD mortality is justified by given 
socioeconomic changes in Poland, in recent 
decades. However, the role of clinical control 
of CVD cannot be neglected. After 1990 the 
Polish population has an increasing access to 
modern therapeutical measures, including 
effective medical technologies and effective 
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medicaments used in the treatment of CVD. In 
Poland, the contribution of those factors to the 
diminished CHD mortality could be as large as 
37% [8]. The effect is likely to reflect not only a 
better access to modern pharmacological ma-
na gements but also could be attributed to some 
changes in health care organization including 
physician-patient interactions. Social aspects 
could play a role and result in improved com-
pliance of patients thus leading to stronger 
preventive outcomes in patients with chronic 
CVD [11]. 
Our findings showed a negative correlation 
between country-wide sale of antihypertensive 
drugs and CHD mortality, particularly in older 
segment of the Polish population. The result 
corresponds with a view concerning beneficial 
effect of pharmacological prevention of CHD 
mortality. Such effect was also seen in other 
study that addressed a risk of so called compo-
site CVD events, stroke and all-cause mortality 
[12]. A large meta-analysis covering more than 
40000 patients with hypertension provided 
interesting evidence concerning cardiovascular 
events and mortality: antihypertensive therapy 
was associated with the reduction of all-cause 
mortality rate by 13%, the risk of death from 
all-cardiac causes by 18%, CV events by 21, and 
stroke by 30%, including fatal stroke by 39% 
[13]. With regard to our findings it is of relevance 
that the gain is much larger in older patients 
than in young patients with hypertension [14]. 
It remains unknown to what extent the age-
related difference reflects age-related duration 
of disease and, consequently, age-related 
duration of the treatment. Such explanation 
cannot be ignored when discussing no apparent 
effect of the treatment of hypertension on CHD 
mortality over the period of 4-5 years [15].
Our findings did not show major differences 
between correlations provided by different 
groups of antihypertensive drugs analyzed in 
the study. The study protocol hampers a more 
detailed discussion of that point. The ecological 
approach used in our analysis has well-known 
limitations but a general conclusion about a 
beneficial impact of increased access of the 
population to modern antihypertensive therapy 
on a risk of CVD mortality in that population 
seems to be convincing. We did not see a similar 
effect in relation to HT mortality. A lack of such 
effect could be explained by a relatively in-
frequent occurrence of HT as a reported cause 
of death in Poland. Death certificates usually 
include fatal complication of HT thus making 
this diagnosis an unreliable index of cause-
specific mortality, with a very limited pertinence 
to conclusive statistical analyses.
Conclusions
In Poland, an improved access of the 
population to pharmacological control of HT, as 
suggested by increased country-wide sale of 
modern antihypertensive drugs, is associated 
with an apparent reduction in mortality from 
CVD but not from HT. The latter finding might 
reflect imprecise definition of HT as a cause of 
death or the fact that HT leads to other 
cardiologic events usually repor ted as a cause 
of death. The findings seem to confirm an 
important contribution of pharma cological 
measures in prevention of CVD mor tality, in 
addition to the well explored role of socio-
economic and life-style factors, in Po land. 
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